Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AVDL
stocks logo

AVDL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
80.30M
+59.29%
0.050
-266.6%
80.07M
+52.48%
0.183
-466.56%
89.54M
+31.42%
0.130
-360%
Estimates Revision
The market is revising Upward the revenue expectations for Avadel Pharmaceuticals plc (AVDL) for FY2025, with the revenue forecasts being adjusted by 2.27% over the past three months. During the same period, the stock price has changed by 35.50%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+29.79%
In Past 3 Month
Stock Price
Go Up
up Image
+35.50%
In Past 3 Month
Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 19.93 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 19.93 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
10 Hold
0 Sell
Hold
Current: 21.355
sliders
Low
18.50
Averages
19.93
High
22.50
Current: 21.355
sliders
Low
18.50
Averages
19.93
High
22.50
Wells Fargo
Equal Weight
maintain
$20
2025-11-20
Reason
Wells Fargo
Price Target
$20
2025-11-20
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $20 and keeps an Equal Weight rating on the shares. The firm says updated Alkermes' (ALKS) offer looks better to Wells, with a similar upfront but better CVR terms that it thinks are likely to pay out.
Truist
initiated
$50
2025-11-11
Reason
Truist
Price Target
$50
2025-11-11
initiated
Reason
Truist initiated coverage of Alkermes (ALKS) with a Buy rating and $50 price target. The firm values the base business and cash at about $29 per share, which it sees "setting a high floor" heading into Phase 2 Vibrance-2 data in narcolepsy type 2. Narcolepsy type 1 alone is worth $8 per share in the firm's sum-of-the-parts valuation, while NT2 and idiopathic hypersomnia contribute $8 per share and $5 per share, respectively, the analyst tells investors. Alkermes "doubling down" in sleep space with the acquisition of Avadel (AVDL) is a strategic move that gives it a first-mover advantage over Takeda (TAK), the analyst added.
UBS
Buy
to
Neutral
downgrade
$20
2025-10-28
Reason
UBS
Price Target
$20
2025-10-28
downgrade
Buy
to
Neutral
Reason
UBS downgraded Avadel Pharmaceuticals (AVDL) to Neutral from Buy with an unchanged price target of $20 after Alkermes (ALKS) announced an agreement to acquire Avadel for $18.50/share plus a contingent value right entitling shareholders to a $1.50 per share potential payment contingent on the FDA approval of Lumryz in idiopathic hypersomnia.
Morgan Stanley
Morgan Stanley
Overweight
maintain
$180 -> $183
2025-10-24
Reason
Morgan Stanley
Morgan Stanley
Price Target
$180 -> $183
2025-10-24
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Jazz Pharmaceuticals (JAZZ) to $183 from $180 and keeps an Overweight rating on the shares after the company announced a settlement of ongoing patent litigation with Avadel (AVDL) over high sodium oxybate Lumryz. The firm now includes royalty revenues from Lumryz in its estimates.
Deutsche Bank
David Hoang
Buy -> Hold
downgrade
$20
2025-10-23
Reason
Deutsche Bank
David Hoang
Price Target
$20
2025-10-23
downgrade
Buy -> Hold
Reason
Deutsche Bank analyst David Hoang downgraded Avadel Pharmaceuticals (AVDL) to Hold from Buy with a $20 price target after the company entered into a definitive agreement to be acquired by Alkermes (ALKS) in an all-cash transaction for up to $20.00 per share - $18.50 per share plus a contingent value right of $1.50 per share.
Piper Sandler
David Amsellem
Overweight
maintain
$38 -> $45
2025-10-23
Reason
Piper Sandler
David Amsellem
Price Target
$38 -> $45
2025-10-23
maintain
Overweight
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on Alkermes (ALKS) to $45 from $38 and keeps an Overweight rating on the shares in the wake of the company's plans to acquire Avadel (AVDL). The firm surmises that the relatively muted market reaction to what is a significantly accretive transaction is likely a nod to the longer-term uncertainty associated with the Lumryz sales trajectory amid the eventual availability of multiple orexin 2 receptor agonists. That said, Piper envisions a sizable role for oxybate products in a world with OX2R agonists.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Avadel Pharmaceuticals PLC (AVDL.O) is 30.89, compared to its 5-year average forward P/E of 131.80. For a more detailed relative valuation and DCF analysis to assess Avadel Pharmaceuticals PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
131.80
Current PE
30.89
Overvalued PE
931.39
Undervalued PE
-667.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
34.14
Undervalued EV/EBITDA
11.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.84
Current PS
0.00
Overvalued PS
6.42
Undervalued PS
3.26
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AVDL News & Events

Events Timeline

(ET)
2025-11-19
06:11:42
Alkermes Raises Acquisition Bid for Avadel Pharmaceuticals to $22.50 per Share
select
2025-11-17 (ET)
2025-11-17
06:11:58
Avadel board determines Lundbeck's proposal is better than Alkermes' offer
select
2025-11-14 (ET)
2025-11-14
12:50:17
Truist believes Alkermes can present a counteroffer that the Avadel board will find acceptable.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
03:20 AMGlobenewswire
Gulf Island Fabrication, Inc. (GIFI) to Sell to IES Holdings, Inc. for $12.00 per Share
  • Potential Violation Investigation: Halper Sadeh LLC is investigating Gulf Island Fabrication, Inc. (NASDAQ: GIFI) regarding its sale to IES Holdings, Inc. for $12.00 per share in cash, which may involve violations of federal securities laws, potentially impacting shareholder rights.
  • Shareholder Rights Protection: The law firm encourages Gulf Island shareholders to learn about their rights and options, potentially seeking increased compensation or other relief measures, thereby enhancing shareholder influence in the transaction.
  • Investigation of Other Companies: In addition to GIFI, Halper Sadeh is also investigating transactions involving Avadel Pharmaceuticals plc and Jamf Holding Corp., which involve acquisitions by Alkermes plc and Francisco Partners respectively, indicating a broad focus on multiple companies.
  • Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, aiming to support affected shareholders and emphasizing its expertise in securities fraud and corporate misconduct.
[object Object]
Preview
8.5
00:21 AMGlobenewswire
Gulf Island Fabrication Shareholders to Receive $12 Cash per Share in IES Holdings Deal
  • Shareholder Returns: Gulf Island Fabrication, Inc. is set to be sold to IES Holdings, Inc. for $12 cash per share, which is expected to provide significant cash returns to shareholders, enhancing the investment appeal of the company.
  • Voting Arrangement: The shareholder vote is scheduled for January 13, 2026, allowing ample time for shareholders to evaluate the terms of the transaction and make informed decisions.
  • Legal Support: Monteverde & Associates PC, acting as the representative law firm, has recovered millions for shareholders, demonstrating its strong capabilities and reputation in securities class action litigation.
  • Market Reaction: The announcement of this transaction may influence Gulf Island's stock price movements, prompting investors to monitor market reactions and the potential implications for the company's future development.
[object Object]
Preview
8.5
12-04Globenewswire
Alkermes to Acquire Avadel; Shareholder Vote Scheduled for January 2026
  • Acquisition Agreement: Alkermes has reached an agreement to acquire all issued ordinary shares of Avadel, which is expected to enhance Alkermes' market position in the biopharmaceutical sector.
  • Shareholder Voting Schedule: Avadel has begun mailing a proxy statement to shareholders, who will vote on the acquisition at a special meeting scheduled for January 12, 2026, ensuring shareholder engagement in the decision-making process.
  • Legal Compliance Procedure: The transaction will be implemented via a scheme of arrangement under Part 9 of the Irish Companies Act, ensuring adherence to relevant laws and minimizing legal risks associated with the acquisition.
  • Transparency in Information Disclosure: Avadel has filed the Definitive Proxy Statement with the SEC, ensuring shareholders receive comprehensive information prior to voting, thereby enhancing transaction transparency and shareholder trust.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Avadel Pharmaceuticals PLC (AVDL) stock price today?

The current price of AVDL is 21.355 USD — it has decreased -0.02 % in the last trading day.

arrow icon

What is Avadel Pharmaceuticals PLC (AVDL)'s business?

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

arrow icon

What is the price predicton of AVDL Stock?

Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 19.93 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Avadel Pharmaceuticals PLC (AVDL)'s revenue for the last quarter?

Avadel Pharmaceuticals PLC revenue for the last quarter amounts to 77.47M USD, increased 54.86 % YoY.

arrow icon

What is Avadel Pharmaceuticals PLC (AVDL)'s earnings per share (EPS) for the last quarter?

Avadel Pharmaceuticals PLC. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Avadel Pharmaceuticals PLC (AVDL)'s fundamentals?

The market is revising Upward the revenue expectations for Avadel Pharmaceuticals plc (AVDL) for FY2025, with the revenue forecasts being adjusted by 2.27% over the past three months. During the same period, the stock price has changed by 35.50%.
arrow icon

How many employees does Avadel Pharmaceuticals PLC (AVDL). have?

Avadel Pharmaceuticals PLC (AVDL) has 188 emplpoyees as of December 05 2025.

arrow icon

What is Avadel Pharmaceuticals PLC (AVDL) market cap?

Today AVDL has the market capitalization of 2.09B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free